NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

Pfizer (PFE) announced on Tuesday that a mid-stage trial evaluating a monthly maintenance dosing regimen of its experimental obesity drug indicated that the GLP-1 receptor agonist PF’3944 (MET-097i) ...

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

PHILADELPHIA -- Pfizer and BioNTech said Tuesday they have submitted Covid-19 vaccine data on children ages 5 to 11 to the US Food and Drug Administration for initial review, but are not yet seeking ...

Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile ‌obesity drug from its recent $10 billion Metsera purchase that raises ‌questions about its tolerability for patients, and ...

Pfizer and BioNTech announced Monday their coronavirus vaccine was more than 90% effective in preventing COVID-19 among those without evidence of prior infection, hailing the development as “a great ...

Patients who switched from weekly to monthly maintenance dosing of an experimental Pfizer obesity drug achieved an average placebo-adjusted weight loss of up to 12.3% in a mid-stage study, results ...

An interim analysis of safety data showed no increased risk associated with Pfizer’s respiratory syncytial virus vaccine when given to pregnant women, researchers reported recently in JAMA. The FDA ...

Boltz Bags $28M Funding and Pfizer Partnership for Biomolecular AI Boost Your email has been sent Pfizer and Boltz have announced a collaboration aimed at expanding the use of advanced biomolecular AI ...